Skinvisible reports licensee success in netherton syndrome clinical studies

Las vegas, nv / access newswire / january 23, 2025 / skinvisible pharmaceuticals, inc. ("skinvisible" or "the company"), (otcqb:skvi), an innovative topical and transdermal pharmaceutical research and development company, with proprietary invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee quoin pharmaceuticals' progress in netherton syndrome treatment. skinvisible granted quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for netherton syndrome.
QNRX Ratings Summary
QNRX Quant Ranking